Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-20
DOI
10.1186/s40425-018-0440-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation
- (2018) Steve J Edwards et al. HEALTH TECHNOLOGY ASSESSMENT
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma
- (2017) Sergio Fernández-Pello et al. EUROPEAN UROLOGY
- Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation
- (2017) Aristotle Bamias et al. ONCOLOGIST
- Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
- (2017) Jordan Amdahl et al. PLoS One
- Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
- (2017) Billy Amzal et al. PLoS One
- Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
- (2017) S. de Groot et al. QUALITY OF LIFE RESEARCH
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
- (2016) Francesca Tartari et al. CANCER TREATMENT REVIEWS
- Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada
- (2016) J. Amdahl et al. Current Oncology
- Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Nicholas J Kassebaum et al. LANCET
- Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
- (2016) Xinan Sheng et al. Oncotarget
- Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients
- (2015) Hideyuki Akaza et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods
- (2015) Elamin H. Elbasha et al. MEDICAL DECISION MAKING
- Landmarks in the diagnosis and treatment of renal cell carcinoma
- (2014) Jaimin R. Bhatt et al. Nature Reviews Urology
- Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US
- (2014) Allison Perrin et al. JOURNAL OF MEDICAL ECONOMICS
- Model Parameter Estimation and Uncertainty Analysis
- (2012) Andrew H. Briggs et al. MEDICAL DECISION MAKING
- Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting
- (2012) Bin Wu et al. PLoS One
- Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
- (2009) G Mickisch et al. BRITISH JOURNAL OF CANCER
- Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
- (2009) Martin Hoyle et al. VALUE IN HEALTH
- Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma
- (2008) Edit Remák et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started